Repetitive Therapy with Levosimendan Effectively Reduces NT-proBNP Levels and NYHA-Class in Heart Failure Patients A Case Report

被引：1
|
作者：
Wechsler, Maximilian [1 ]
Schwinger, Robert H. G. [1 ]
机构：
[1] Lehrkrankenhaus Univ Regensburg, Kliniken Nordober Pfalz AG, Klinikum Weiden, Med Klin 2, Sollnerstr 16, D-92637 Weiden, Germany
来源：
AKTUELLE KARDIOLOGIE | 2022年 / 11卷 / 05期
关键词：
Levosimendan; NT-proBNP; chronical heartfailure; ICM; ESC GUIDELINES; DIAGNOSIS;
D O I：
10.1055/a-1799-7077
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since any cardiac decompensation with subsequent hospitalization worsens the prognosis of the patient further, it is important to prevent cardiac decompensations. A normal NT-proBNP value is a "rule-out" parameter for heart failure. Measurement of NT-proBNP may help to estimate the intraindividual risk of cardiac decompensation and may guide intensification of heart failure treatment. Levosimendan therapy in addition to OMT improves pump function and thus reduces the risk of cardiac decompensation. The present case illustrates the benefit of repetitive therapy with levosimendan in addition to OMT following ESC Guideline-directed treatment.
引用
收藏
页码：484 / 489
页数：6
相关论文
共 50 条
  • [31] Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure
    Hammerer-Lercher, Angelika
    Halfinger, Bernhard
    Sarg, Bettina
    Mair, Johannes
    Puschendorf, Bernd
    Griesmacher, Andrea
    Guzman, Norberto A.
    Lindner, Herbert H.
    [J]. CLINICAL CHEMISTRY, 2008, 54 (05) : 858 - 865
  • [32] Measurement of NT-proBNP with LOCI® technology in heart failure patients
    Gruson, D.
    Ahn, Sylvie A.
    Lepoutre, Thibault
    Rousseau, Michel F.
    [J]. CLINICAL BIOCHEMISTRY, 2012, 45 (1-2) : 171 - 174
  • [33] The mortality prediction of NT-proBNP in elderly patients with heart failure
    Kurt, O.
    Balta, S.
    Cakar, M.
    Unlu, M.
    Arslan, E.
    Demirkol, S.
    [J]. EUROPEAN GERIATRIC MEDICINE, 2013, 4 (02) : 121 - 121
  • [34] The relationship between NT-proBNP and Depression in Patients with Heart Failure
    YingHui GAO
    Lin LIU
    Yu WANG
    Chao LIU
    [J]. Journal of Geriatric Cardiology, 2017, 14 (11) - 716
  • [35] Prognostic Significance of First Week NT-ProBNP Levels in Heart Failure
    Kabi, Shobhitendu
    Dalai, Siba Prasad
    Jena, Kamal Kant
    Samal, Akshaya Kumar
    Panda, Baikuntha Nath
    Dhar, Srikant Kumar
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2018, 12 (09) : OC14 - OC17
  • [36] NT-ProBNP Levels in Saliva and Its Clinical Relevance to Heart Failure
    Foo, Jared Yong Yang
    Wan, Yunxia
    Kostner, Karam
    Arivalagan, Alicia
    Atherton, John
    Cooper-White, Justin
    Dimeski, Goce
    Punyadeera, Chamindie
    [J]. PLOS ONE, 2012, 7 (10):
  • [37] NT-proBNP in monitoring treatment of patients with congestive heart failure
    Al-Meslmani, Bssam M.
    Fahoum, Sahar K.
    Shamia, Marwan G.
    [J]. CLINICAL LABORATORY, 2007, 53 (1-2) : 35 - 39
  • [38] NT-proBNP in nursing home patients with and without heart failure
    Daae, Abrahamsen B. C.
    Ruths, S.
    Nygaard, H. A.
    [J]. SWISS MEDICAL WEEKLY, 2009, 139 (33-34) : 166S - 166S
  • [39] The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement
    Sedlak, Tara L.
    Chandavimol, Mann
    Calleja, Anna
    Clark, Catherine
    Edmonds, Margaret
    Pu, Aihua
    Humphries, Karin H.
    Ignaszewski, Andrew
    [J]. OPEN CARDIOVASCULAR MEDICINE JOURNAL, 2008, 2 : 36 - 40
  • [40] Heart Failure: Therapy Control after NT-ProBNP without Benefit
    Kessing, Richard
    [J]. AKTUELLE KARDIOLOGIE, 2019, 8 (01)
12345